Aphria Inc. Receives EU GMP Certification for Subsidiary ARA-Avanti Rx Analytics

Published: January 22, 2020

Aphria Inc. Receives EU GMP Certification for Subsidiary ARA-Avanti Rx Analytics

Aphria Inc. announced that it has received its European Union Good Manufacturing Practices (“EU GMP“) certification in respect of medicinal products for human use and investigational medicinal products for human use, from the Malta Medicines Authority (“MMA“) at the Company’s subsidiary, ARA – Avanti Rx Analytics.

Aphria selected the MMA to perform the EU GMP audit as the criteria and certification thresholds established by the MMA are among the most stringent and demanding in the EU. The certification will allow the Company to ship bulk and finished dried flower, as well as bulk and finished cannabis oil for medicinal use in permitted jurisdictions throughout the European Union.

“We believe that this is a game changer for Aphria Inc. and will significantly advance our leadership in permissible medical cannabis markets across Europe, where demand for product is strong,” said Irwin D. Simon, Chief Executive Officer. “With 2.4 million square feet of licensed production capacity of up to 255,000 kilograms, state-of-the-art greenhouses and labs, and our global infrastructure, we believe Aphria is well positioned to lead in the Canadian and international markets.”

Aphria’s German operations have been preparing for the importation of EU-GMP certified cannabis from Canada, allowing for shipments to the Company’s German subsidiary CC Pharma GmbH (“CC Pharma”) in order to leverage CC Pharma’s expansive in-country distribution network. The Company anticipates that its first shipments of medical cannabis to CC Pharma will occur in its fourth quarter of its fiscal 2020.

Recent News

View All News Items

Latest Article

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

Legalization 2.0: IP and Regulatory Considerations for Edibles, Extracts and Topicals

The legalization of cannabis edibles, extracts and topicals will expand the cannabis market and create new opportunities for producers, innovators and investors. According to a recent report from Deloitte, the Canadian market for these new cannabis products is expected to be worth $2.7 billion annually, with edibles accounting for more than half ($1.6 billion).

 

Read Article